Category Archives: Safety Pharmacology

New textbook chapter – Modelling Drug Induced Proarrhythmic Risk and a challenge for whole-heart computational modellers

Posted on July 20, 2023 by Gary Mirams

A little note to say that a textbook chapter I wrote last year is now online and available as part of the Springer Reference work “Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays“ The chapter is available here, and if … Continue reading →

Posted in Drug action, Safety Pharmacology, Tissue Simulations, Unexplained | Tagged , , , , , | Leave a comment

2021 CiPA in-silico Modelling Workshop

Posted on June 14, 2021 by Gary Mirams

Abstract submission for the 2021 CiPA in-silico modelling meeting is open now. Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , , , , , | Leave a comment

Job Available: Research Software Engineer

Posted on February 11, 2019 by Gary Mirams

Edit: please note the deadline for applications has now passed. Here’s a great opportunity to join our team at the University of Nottingham on a 5 year Research Software Engineering (RSE) position: https://www.nottingham.ac.uk/jobs/currentvacancies/ref/IS046219 The deadline for applications is 3rd March … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Numerics, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , | Leave a comment

Postdoctoral Research Positions Available

Posted on December 15, 2018 by Gary Mirams

N.B. 16th Jan 2019 – the applications for these positions are now closed. This post is to let people know about some opportunities for postdoctoral research here in the Centre for Mathematical Medicine & Biology, based in Mathematical Sciences, University … Continue reading →

Posted in Action Potential Models, Drug action, Experimental Design, Future developments, Ion Channel Models, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , , , | 1 Comment

A report on the Toronto CiPA in-silico modelling workshop

Posted on July 16, 2018 by Gary Mirams

This is a follow-up to this post advertising the workshop. On the 9th November 2017 the CiPA in-silico Working Group hosted a meeting in Toronto General Hospital that the Cardiac Physiome meeting kindly let us run as a satellite meeting … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , , , , , , | 2 Comments

Postdoc position available

Posted on September 4, 2017 by Gary Mirams

N.B. This position is now closed. Another short post, just to advertise a postdoctoral research associate (PDRA) position available to work with me. It’s a two year position, based at the Centre for Mathematical Medicine & Biology at the University … Continue reading →

Posted in Drug action, Experimental Design, Future developments, Ion Channel Models, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , | Leave a comment

CiPA in-silico modelling meeting

Posted on August 31, 2017 by Gary Mirams

There’s an effort underway to evaluate, improve and implement mathematical models of cardiac electrophysiology for pharmaceutical cardiac safety testing and regulatory practice. In particular, to be part of a more mechanistic and accurate in-vitro assessment of pro-arrhythmic risk than the … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , | 1 Comment

Arrhythmic risk: regression, single cell biophysics, or big tissue simulations?

Posted on March 27, 2017 by Gary Mirams

On the 15th March I presented at an FDA public Advisory Committee hearing on the proposals of the CiPA initative. CiPA aims to replace the current testing for increased drug-induced Torsade de Pointes (TdP) arrhythmic risk, which is a human … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Model Development, Safety Pharmacology, Tissue Simulations | Tagged , , , , , , , | 3 Comments

Uncertainty quantification for ion channel screening and risk prediction

Posted on November 23, 2016 by Gary Mirams

This post accompanies our new paper in Wellcome Open Research. Regular readers of this blog will know that I worry about uncertainty in the numbers we are using to model drug action on electrophysiology quite a lot – see our … Continue reading →

Posted in Drug action, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , | 4 Comments

Should I work with IC50s or pIC50s?

Posted on June 13, 2016 by Gary Mirams

When you are expressing how much a drug inhibits something, it’s common to fit a Hill curve through a graph of concentration against % inhibition as shown here: In our case this is often ‘% inhibition’ for a given ionic … Continue reading →

Posted in Drug action, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , , , , | 1 Comment